Nan Chen on Impact of Anthracyclines in High Genomic Risk Node Negative HR Positive HER2 Negative Breast Cancer

Nan Chen, MD, of the University of Chicago Medicine, Chicago, discusses the impact of anthracyclines in high genomic risk node-negative...
4 hours ago
from: The ASCO Post

Anthracycline, Breast cancer, Chemotherapy, Oncology, Taxane

More about this

- When to Use Anthracyclines in Early Breast Cancer
Post hoc data from TAILORx show that adding an anthracycline to taxane-based chemotherapy benefits patients with HR-positive early breast...
from: Medscape

- Research Offers Further Insight into Chemo Scheduling for Early Breast Cancer
Study sought to optimize chemo dosing schedule for patients with node-positive or high-risk node-negative breast cancer.
from: Cleveland Clinic

- SABCS 2024: Anthracyclines May Improve Survival in High-Risk Breast Cancer, But Risks Must Be Weighed
In an interview with Pharmacy Times®, Nan Chen, MD, breast medical oncologist from the University of Chicago, shared that patient with high...
from: Pharmacy Times

- Homing in on Anthracyclines' High-Risk Niche in Early Breast Cancer
SAN ANTONIO -- Women with larger, genomically high-risk breast cancers had significantly lower risk of distant metastasis with chemotherapy...
from: MedPage Today

- Adjuvant anthracycline- plus taxane-based chemotherapy regimen improves survival in high-risk breast cancer patients
Patients with early-stage, node-negative, hormone receptor (HR)-positive, HER2- negative breast cancer who have a high risk of recurrence...
from: News-Medical